Iron in neurodegenerative disorders of protein misfolding: A case of prion disorders and parkinson's disease

Antioxidants and Redox Signaling

Volumn 21, Issue 3, 2014, Pages 471-484

  Singh, Neena ^a   Haldar, Swati ^a   Tripathi, Ajai K ^a   McElwee, Matthew K ^a   Horback, Katharine ^a   Beserra, Amber ^b  

^a CASE WESTERN RESERVE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b CASE WESTERN RESERVE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA SYNUCLEIN; FERRITIN; IRON; PRION PROTEIN; PRION;

CEREBROSPINAL FLUID; CONFORMATIONAL TRANSITION; HOMEOSTASIS; HUMAN; IRON DEFICIENCY; IRON METABOLISM; IRON STORAGE; IRON TRANSPORT; NEURODEGENERATION WITH BRAIN IRON ACCUMULATION; NEUROTOXICITY; NONHUMAN; OXIDATIVE STRESS; PARKINSON DISEASE; PATHOGENESIS; POLYMERIZATION; PRION DISEASE; PRIORITY JOURNAL; PROTEIN FOLDING; REVIEW; SCRAPIE; SPORADIC CREUTZFELDT JAKOB DISEASE; SUBSTANTIA NIGRA; DEGENERATIVE DISEASE; METABOLISM; NERVE CELL; PATHOLOGY; PRION; PROTEOSTASIS DEFICIENCY;

HUMANS; IRON; NEURODEGENERATIVE DISEASES; NEURONS; PARKINSON DISEASE; PRION DISEASES; PRIONS; PROTEIN FOLDING; PROTEOSTASIS DEFICIENCIES;

EID: 84903755665     PISSN: 15230864     EISSN: 15577716     Source Type: Journal    
DOI: 10.1089/ars.2014.5874     Document Type: Review

References (183)

1. Aguib Y, Heiseke A, Gilch S, Riemer C, Baier M, Schatzl HM, and Ertmer A. Autophagy induction by trehalose counteracts cellular prion infection. Autophagy 5: 361-369, 2009.
2. Aguirre P, Urrutia P, Tapia V, Villa M, Paris I, Segura- Aguilar J, and Nunez MT. The dopamine metabolite aminochrome inhibits mitochondrial complex I and modifies the expression of iron transporters DMT1 and FPN1. Biometals 25: 795-803, 2012.
3. Aguzzi A and Calella AM. Prions: protein aggregation and infectious diseases. Physiol Rev 89: 1105-1152, 2009.
4. Aguzzi A and Falsig J. Prion propagation, toxicity and degradation. Nat Neurosci 15: 936-939, 2012.
5. Aguzzi A and O'Connor T. Protein aggregation diseases: pathogenicity and therapeutic perspectives. Nat Rev Drug Discov 9: 237-248, 2010.
6. Ahmed I, Liang Y, Schools S, Dawson VL, Dawson TM, and Savitt JM. Development and characterization of a new Parkinson's disease model resulting from impaired autophagy. J Neurosci 32: 16503-16509, 2012.
7. Arduino DM, Esteves AR, Cortes L, Silva DF, Patel B, Grazina M, Swerdlow RH, Oliveira CR, and Cardoso SM. Mitochondrial metabolism in Parkinson's disease impairs quality control autophagy by hampering microtubuledependent traffic. Hum Mol Genet 21: 4680-4702, 2012.
8. Basu S, Mohan ML, Luo X, Kundu B, Kong Q, and Singh N. Modulation of proteinase K-resistant prion protein in cells and infectious brain homogenate by redox iron: implications for prion replication and disease pathogenesis. Mol Biol Cell 18: 3302-3312, 2007.
9. Bender A, Desplats P, Spencer B, Rockenstein E, Adame A, Elstner M, Laub C, Mueller S, Koob AO, Mante M, Pham E, Klopstock T, and Masliah E. TOM40 mediates mitochondrial dysfunction induced by alpha-synuclein accumulation in Parkinson's disease. Plos One 8: e62277, 2013.
10. Bharathi, Indi SS, and Rao KS. Copper- and iron-induced differential fibril formation in alpha-synuclein: TEM study. Neurosci Lett 424: 78-82, 2007.
11. Bhupanapadu Sunkesula SR, Luo X, Das D, Singh A, and Singh N. Iron content of ferritin modulates its uptake by intestinal epithelium: implications for co-transport of prions. Mol Brain 3: 14, 2010.
12. Binolfi A, Rasia RM, Bertoncini CW, Ceolin M, Zweckstetter M, Griesinger C, Jovin TM, and Fernandez CO. Interaction of alpha-synuclein with divalent metal ions reveals key differences: a link between structure, binding specificity and fibrillation enhancement. J Am Chem Soc 128: 9893-9901, 2006.
13. Bonifati V, Rizzu P, van Baren MJ, Schaap O, Breedveld GJ, Krieger E, Dekker MC, Squitieri F, Ibanez P, Joosse M, van Dongen JW, Vanacore N, van Swieten JC, Brice A, Meco G, van Duijn CM, Oostra BA, and Heutink P. Mutations in the DJ-1 gene associated with autosomal recessive early-onset parkinsonism. Science 299: 256-259, 2003.
14. Borie C, Gasparini F, Verpillat P, Bonnet AM, Agid Y, Hetet G, Brice A, Durr A, and Grandchamp B. Association study between iron-related genes polymorphisms and Parkinson's disease. J Neurol 249: 801-804, 2002.
15. Bueler H, Fischer M, Lang Y, Bluethmann H, Lipp HP, DeArmond SJ, Prusiner SB, Aguet M, and Weissmann C. Normal development and behaviour of mice lacking the neuronal cell-surface PrP protein. Nature 356: 577-582, 1992.
16. Bush AI and Curtain CC. Twenty years of metalloneurobiology: where to now. Eur Biophys J 37: 241-245, 2008.
17. Cahill CM, Lahiri DK, Huang X, and Rogers JT. Amyloid precursor protein and alpha synuclein translation, implications for iron and inflammation in neurodegenerative diseases. Biochim Biophys Acta 1790: 615-628, 2009.
18. Carroll CB, Zeissler ML, Chadborn N, Gibson K, Williams G, Zajicek JP, Morrison KE, and Hanemann CO. Changes in iron-regulatory gene expression occur in human cell culture models of Parkinson's disease. Neurochem Int 59: 73-80, 2011.
19. Castellani RJ, Siedlak SL, Perry G, and Smith MA. Sequestration of iron by Lewy bodies in Parkinson's disease. Acta Neuropathol 100: 111-114, 2000.
20. Castilla J, Saa P, Hetz C, and Soto C. In vitro generation of infectious scrapie prions. Cell 121: 195-206, 2005.
21. Caughey B, Baron GS, Chesebro B, and Jeffrey M. Getting a grip on prions: oligomers, amyloids, and pathological membrane interactions. Annu Rev Biochem 78: 177-204, 2009.
22. Chartier-Harlin MC, Kachergus J, Roumier C, Mouroux V, Douay X, Lincoln S, Levecque C, Larvor L, Andrieux J, Hulihan M, Waucquier N, Defebvre L, Amouyel P, Farrer M, and Destee A. Alpha-synuclein locus duplication as a cause of familial Parkinson's disease. Lancet 364: 1167-1169, 2004.
23. Chinta SJ and Andersen JK. Redox imbalance in Parkinson's disease. Biochim Biophys Acta 1780: 1362-1367, 2008.
24. Chinta SJ, Mallajosyula JK, Rane A, and Andersen JK. Mitochondrial alpha-synuclein accumulation impairs complex I function in dopaminergic neurons and results in increased mitophagy in vivo. Neurosci Lett 486: 235-239, 2010.
25. Choi BR, Lee J, Kim SY, Yim I, Kim EH, and Woo HJ. Prion protein conversion induced by trivalent iron in vesicular trafficking. Biochem Biophys Res Commun 432: 539-544, 2013.
26. Choi CJ, Kanthasamy A, Anantharam V, and Kanthasamy AG. Interaction of metals with prion protein: possible role of divalent cations in the pathogenesis of prion diseases. Neurotoxicology 27: 777-787, 2006.
27. Chou AP, Li S, Fitzmaurice AG, and Bronstein JM. Mechanisms of rotenone-induced proteasome inhibition. Neurotoxicology 31: 367-372, 2010.
28. Clark IE, Dodson MW, Jiang C, Cao JH, Huh JR, Seol JH, Yoo SJ, Hay BA, and Guo M. Drosophila pink1 is required for mitochondrial function and interacts genetically with parkin. Nature 441: 1162-1166, 2006.
29. Conway KA, Harper JD, and Lansbury PT. Accelerated in vitro fibril formation by a mutant alpha-synuclein linked to early-onset Parkinson disease. Nat Med 4: 1318-1320, 1998.
30. Cosseddu GM, Nonno R, Vaccari G, Bucalossi C, Fernandez-Borges N, Di Bari MA, Castilla J, and Agrimi U. Ultra-efficient PrP(Sc) amplification highlights potentialities and pitfalls of PMCA technology. Plos Pathog 7: e1002370, 2011.
31. Cuervo AM, Stefanis L, Fredenburg R, Lansbury PT, and Sulzer D. Impaired degradation of mutant alpha-synuclein by chaperone-mediated autophagy. Science 305: 1292-1295, 2004.
32. Das D, Luo X, Singh A, Gu Y, Ghosh S, Mukhopadhyay CK, Chen SG, Sy MS, Kong Q, and Singh N. Paradoxical role of prion protein aggregates in redox-iron induced toxicity. Plos One 5: e11420, 2010.
33. Davies P, Moualla D, and Brown DR. Alpha-synuclein is a cellular ferrireductase. Plos One 6: e15814, 2011.
34. Deleault NR, Harris BT, Rees JR, and Supattapone S. Formation of native prions from minimal components in vitro. Proc Natl Acad Sci U S A 104: 9741-9746, 2007.
35. Devi L, Raghavendran V, Prabhu BM, Avadhani NG, and Anandatheerthavarada HK. Mitochondrial import and accumulation of alpha-synuclein impair complex I in human dopaminergic neuronal cultures and Parkinson disease brain. J Biol Chem 283: 9089-9100, 2008.
36. Dexter DT, Wells FR, Lees AJ, Agid F, Agid Y, Jenner P, and Marsden CD. Increased nigral iron content and alterations in other metal ions occurring in brain in Parkinson's disease. J Neurochem 52: 1830-1836, 1989.
37. Duce JA and Bush AI. Biological metals and Alzheimer's disease: implications for therapeutics and diagnostics. Prog Neurobiol 92: 1-18, 2010.
38. El-Agnaf OM, Jakes R, Curran MD, and Wallace A. Effects of the mutations Ala30 to Pro and Ala53 to Thr on the physical and morphological properties of alpha-synuclein protein implicated in Parkinson's disease. FEBS Lett 440: 67-70, 1998.
39. Ertmer A, Huber V, Gilch S, Yoshimori T, Erfle V, Duyster J, Elsasser HP, and Schatzl HM. The anticancer drug imatinib induces cellular autophagy. Leukemia 21: 936-942, 2007.
40. Exner N, Lutz AK, Haass C, and Winklhofer KF. Mitochondrial dysfunction in Parkinson's disease: molecular mechanisms and pathophysiological consequences. EMBO J 31: 3038-3062, 2012.
41. Febbraro F, Giorgi M, Caldarola S, Loreni F, and Romero- Ramos M. Alpha-synuclein expression is modulated at the translational level by iron. Neuroreport 23: 576-580, 2012.
42. Fernaeus S, Halldin J, Bedecs K, and Land T. Changed iron regulation in scrapie-infected neuroblastoma cells. Brain Res Mol Brain Res 133: 266-273, 2005.
43. Fernaeus S and Land T. Increased iron-induced oxidative stress and toxicity in scrapie-infected neuroblastoma cells. Neurosci Lett 382: 217-220, 2005.
44. Fernaeus S, Reis K, Bedecs K, and Land T. Increased susceptibility to oxidative stress in scrapie-infected neuroblastoma cells is associated with intracellular iron status. Neurosci Lett 389: 133-136, 2005.
45. Friedlich AL, Tanzi RE, and Rogers JT. The 5-untranslated region of Parkinson's disease alpha-synuclein messengerRNA contains a predicted iron responsive element. Mol Psychiatry 12: 222-223, 2007.
46. Fritschi SK, Eftekharzadeh B, Manfredi G, Hamaguchi T, Heilbronner G, Nagarathinam A, Langer F, Eisele YS, Walker L, and Jucker M. The Prion-Like Aspect of Alzheimer Pathology. Berlin Heidelberg Springer-Verlag 2013
47. Fuchs J, Nilsson C, Kachergus J, Munz M, Larsson EM, Schule B, Langston JW, Middleton FA, Ross OA, Hulihan M, Gasser T, and Farrer MJ. Phenotypic variation in a large Swedish pedigree due to SNCA duplication and triplication. Neurology 68: 916-922, 2007.
48. Fujioka S and Wszolek ZK. Update on genetics of parkinsonism. Neurodegener Dis 10: 257-260, 2012.
49. Galvin JE, Giasson B, Hurtig HI, Lee VM, and Trojanowski JQ. Neurodegeneration with brain iron accumulation, type 1 is characterized by alpha-, beta-, and gamma-synuclein neuropathology. Am J Pathol 157: 361-368, 2000.
50. Garrick MD, Zhao L, Roth JA, Jiang H, Feng J, Foot NJ, Dalton H, Kumar S, and Garrick LM. Isoform specific regulation of divalent metal (ion) transporter (DMT1) by proteasomal degradation. Biometals 25: 787-793, 2012.
51. Gasser T, Hardy J, and Mizuno Y. Milestones in PD genetics. Mov Disord 26: 1042-1048, 2011.
52. Giasson BI, Duda JE, Murray IV, Chen Q, Souza JM, Hurtig HI, Ischiropoulos H, Trojanowski JQ, and Lee VM. Oxidative damage linked to neurodegeneration by selective alpha-synuclein nitration in synucleinopathy lesions. Science 290: 985-989, 2000.
53. Giasson BI, Uryu K, Trojanowski JQ, and Lee VM. Mutant and wild type human alpha-synucleins assemble into elongated filaments with distinct morphologies in vitro. J Biol Chem 274: 7619-7622, 1999.
54. Gu Y, Fujioka H, Mishra RS, Li R, and Singh N. Prion peptide 106-126 modulates the aggregation of cellular prion protein and induces the synthesis of potentially neurotoxic transmembrane PrP. J Biol Chem 277: 2275-2286, 2002.
55. Gu Y, Hinnerwisch J, Fredricks R, Kalepu S, Mishra RS, and Singh N. Identification of cryptic nuclear localization signals in the prion protein. Neurobiol Dis 12: 133-149, 2003.
56. Gu Y, Luo X, Basu S, Fujioka H, and Singh N. Cellspecific metabolism and pathogenesis of transmembrane prion protein. Mol Cell Biol 26: 2697-2715, 2006.
57. Gu Y, Singh A, Bose S, and Singh N. Pathogenic mutations in the glycosylphosphatidylinositol signal peptide of PrP modulate its topology in neuroblastoma cells. Mol Cell Neurosci 37: 647-656, 2008.
58. Gu Y and Singh N. Doxycycline and protein folding agents rescue the abnormal phenotype of familial CJD H187R in a cell model. Brain Res Mol Brain Res 123: 37-44, 2004.
59. Gu Y, Verghese S, Bose S, Mohan M, and Singh N. Mutant prion protein D202N associated with familial prion disease is retained in the endoplasmic reticulum and forms 'curly' intracellular aggregates. J Mol Neurosci 32: 90-96, 2007.
60. Gu Y, Verghese S, Mishra RS, Xu X, Shi Y, and Singh N. Mutant prion protein-mediated aggregation of normal prion protein in the endoplasmic reticulum: implications for prion propagation and neurotoxicity. J Neurochem 84: 10-22, 2003.
61. Guerreiro RJ, Bras JM, Santana I, Januario C, Santiago B, Morgadinho AS, Ribeiro MH, Hardy J, Singleton A, and Oliveira C. Association of HFE common mutations with Parkinson's disease, Alzheimer's disease and mild cognitive impairment in a Portuguese cohort. BMC Neurol 6: 24, 2006.
62. Haldar S, Beveridge AJ, Wong J, Singh A, Galimberti D, Borroni B, Zhu X, Blevins J, Greenlee J, Perry G, Mukhopadhyay CK, Schmotzer C, and Singh N. A lowmolecular- weight ferroxidase is increased in the CSF of sCJD cases: CSF ferroxidase and transferrin as diagnostic biomarkers for sCJD. Antioxid Redox Signal 19: 1662-1675, 2013.
63. Hara T, Nakamura K, Matsui M, Yamamoto A, Nakahara Y, Suzuki-Migishima R, Yokoyama M, Mishima K, Saito I, Okano H, and Mizushima N. Suppression of basal autophagy in neural cells causes neurodegenerative disease in mice. Nature 441: 885-889, 2006.
64. Hare D, Ayton S, Bush A, and Lei P. A delicate balance: iron metabolism and diseases of the brain. Front Aging Neurosci 5: 34, 2013.
65. Harrison PM and Arosio P. The ferritins: molecular properties, iron storage function and cellular regulation. Biochim Biophys Acta 1275: 161-203, 1996.
66. Hashimoto M, Hsu LJ, Sisk A, Xia Y, Takeda A, Sundsmo M, and Masliah E. Human recombinant NACP/alpha- synuclein is aggregated and fibrillated in vitro: relevance for Lewy body disease. Brain Res 799: 301-306, 1998.
67. Hashimoto M, Hsu LJ, Xia Y, Takeda A, Sisk A, Sundsmo M, and Masliah E. Oxidative stress induces amyloid-like aggregate formation of NACP/alpha-synuclein in vitro. Neuroreport 10: 717-721, 1999.
68. Heiseke A, Aguib Y, Riemer C, Baier M, and Schatzl HM. Lithium induces clearance of protease resistant prion protein in prion-infected cells by induction of autophagy. J Neurochem 109: 25-34, 2009.
69. Heiseke A, Aguib Y, and Schatzl HM. Autophagy, prion infection and their mutual interactions. Curr Issues Mol Biol 12: 87-97, 2010.
70. Henchcliffe C and Beal MF. Mitochondrial biology and oxidative stress in Parkinson disease pathogenesis. Nat Clin Pract Neurol 4: 600-609, 2008.
71. Heo HY, Park JM, Kim CH, Han BS, Kim KS, and Seol W. LRRK2 enhances oxidative stress-induced neurotoxicity via its kinase activity. Exp Cell Res 316: 649-656, 2010.
72. Hsu LJ, Sagara Y, Arroyo A, Rockenstein E, Sisk A, Mallory M, Wong J, Takenouchi T, Hashimoto M, and Masliah E. Alpha-synuclein promotes mitochondrial deficit and oxidative stress. Am J Pathol 157: 401-410, 2000.
73. Hubert N and Hentze MW. Previously uncharacterized isoforms of divalent metal transporter (DMT)-1: implications for regulation and cellular function. Proc Natl Acad Sci U S A 99: 12345-12350, 2002.
74. Irrcher I, Aleyasin H, Seifert EL, Hewitt SJ, Chhabra S, Phillips M, Lutz AK, Rousseaux MW, Bevilacqua L, Jahani-Asl A, Callaghan S, MacLaurin JG, Winklhofer KF, Rizzu P, Rippstein P, Kim RH, Chen CX, Fon EA, Slack RS, Harper ME, McBride HM, Mak TW, and Park DS. Loss of the Parkinson's disease-linked gene DJ-1 perturbs mitochondrial dynamics. Hum Mol Genet 19: 3734-3746, 2010.
75. Jellinger KA. Synuclein and Parkinson's disease an update. In: Emerging Drugs and Targets for Parkinson's Disease edited by Martinez A and Gil C Cambridge, United Kingdom: The Royal Society of Chemistry Publishing, 2013, pp. 175-216.
76. Jeong SY and David S. Glycosylphosphatidylinositolanchored ceruloplasmin is required for iron efflux from cells in the central nervous system. J Biol Chem 278: 27144-27148, 2003.
77. Jesenberger V and Jentsch S. Deadly encounter: ubiquitin meets apoptosis. Nat Rev Mol Cell Biol 3: 112-121, 2002.
78. Jiang H, Song N, Xu H, Zhang S, Wang J, and Xie J. Up-regulation of divalent metal transporter 1 in 6- hydroxydopamine intoxication is IRE/IRP dependent. Cell Res 20: 345-356, 2010.
79. Jin T, Gu Y, Zanusso G, Sy M, Kumar A, Cohen M, Gambetti P, and Singh N. The chaperone protein BiP binds to a mutant prion protein and mediates its degradation by the proteasome. J Biol Chem 275: 38699-38704, 2000.
80. Jucker M and Walker LC. Pathogenic protein seeding in Alzheimer disease and other neurodegenerative disorders. Ann Neurol 70: 532-540, 2011.
81. Kamp F, Exner N, Lutz AK, Wender N, Hegermann J, Brunner B, Nuscher B, Bartels T, Giese A, Beyer K, Eimer S, Winklhofer KF, and Haass C. Inhibition of mitochondrial fusion by alpha-synuclein is rescued by PINK1, Parkin and DJ-1. EMBO J 29: 3571-3589, 2010.
82. Kayed R and Lasagna-Reeves CA. Molecular mechanisms of amyloid oligomers toxicity. J Alzheimers Dis 33 Suppl 1: S67-S78, 2013.
83. Keeney PM, Xie J, Capaldi RA, and Bennett JP, Jr. Parkinson's disease brain mitochondrial complex I has oxidatively damaged subunits and is functionally impaired and misassembled. J Neurosci 26: 5256-5264, 2006.
84. Kim BH, Jun YC, Jin JK, Kim JI, Kim NH, Leibold EA, Connor JR, Choi EK, Carp RI, and Kim YS. Alteration of iron regulatory proteins (IRP1 and IRP2) and ferritin in the brains of scrapie-infected mice. Neurosci Lett 422: 158-163, 2007.
85. Kim NH, Choi JK, Jeong BH, Kim JI, Kwon MS, Carp RI, and Kim YS. Effect of transition metals (Mn, Cu, Fe) and deoxycholic acid (DA) on the conversion of PrPC to PrPres. FASEB J 19: 783-785, 2005.
86. Kim NH, Park SJ, Jin JK, Kwon MS, Choi EK, Carp RI, and Kim YS. Increased ferric iron content and ironinduced oxidative stress in the brains of scrapie-infected mice. Brain Res 884: 98-103, 2000.
87. Kitada T, Asakawa S, Hattori N, Matsumine H, Yamamura Y, Minoshima S, Yokochi M, Mizuno Y, and Shimizu N. Mutations in the parkin gene cause autosomal recessive juvenile parkinsonism. Nature 392: 605-608, 1998.
88. Kondo K, Obitsu S, and Teshima R. Alpha-synuclein aggregation and transmission are enhanced by leucine-rich repeat kinase 2 in human neuroblastoma SH-SY5Y cells. Biol Pharm Bull 34: 1078-1083, 2011.
89. Kostka M, Hogen T, Danzer KM, Levin J, Habeck M, Wirth A, Wagner R, Glabe CG, Finger S, Heinzelmann U, Garidel P, Duan W, Ross CA, Kretzschmar H, and Giese A. Single particle characterization of iron-induced poreforming alpha-synuclein oligomers. J Biol Chem 283: 10992-11003, 2008.
90. Kruger R, Kuhn W, Muller T, Woitalla D, Graeber M, Kosel S, Przuntek H, Epplen JT, Schols L, and Riess O. Ala30Pro mutation in the gene encoding alpha-synuclein in Parkinson's disease. Nat Genet 18: 106-108, 1998.
91. Langston JW, Forno LS, Tetrud J, Reeves AG, Kaplan JA, and Karluk D. Evidence of active nerve cell degeneration in the substantia nigra of humans years after 1-methyl-4- phenyl-1,2,3,6-tetrahydropyridine exposure. Ann Neurol 46: 598-605, 1999.
92. Lee DW, Kaur D, Chinta SJ, Rajagopalan S, and Andersen JK. A disruption in iron-sulfur center biogenesis via inhibition of mitochondrial dithiol glutaredoxin 2 may contribute to mitochondrial and cellular iron dysregulation in mammalian glutathione-depleted dopaminergic cells: implications for Parkinson's disease. Antioxid Redox Signal 11: 2083-2094, 2009.
93. Lee HJ and Lee SJ. Characterization of cytoplasmic alphasynuclein aggregates. Fibril formation is tightly linked to the inclusion-forming process in cells. J Biol Chem 277: 48976-48983, 2002.
94. Lee KS, Raymond LD, Schoen B, Raymond GJ, Kett L, Moore RA, Johnson LM, Taubner L, Speare JO, Onwubiko HA, Baron GS, Caughey WS, and Caughey B. Hemin interactions and alterations of the subcellular localization of prion protein. J Biol Chem 282: 36525-36533, 2007.
95. Lemasters JJ. Selective mitochondrial autophagy, or mitophagy, as a targeted defense against oxidative stress, mitochondrial dysfunction, and aging. Rejuvenation Res 8: 3-5, 2005.
96. Li J, Uversky VN, and Fink AL. Conformational behavior of human alpha-synuclein is modulated by familial Parkinson's disease point mutations A30P and A53T. Neurotoxicology 23: 553-567, 2002.
97. Liu G, Zhang C, Yin J, Li X, Cheng F, Li Y, Yang H, Ueda K, Chan P, and Yu S. Alpha-synuclein is differentially expressed in mitochondria from different rat brain regions and dose-dependently down-regulates complex I activity. Neurosci Lett 454: 187-192, 2009.
98. Loeb V, Yakunin E, Saada A, and Sharon R. The transgenic overexpression of alpha-synuclein and not its related pathology associates with complex I inhibition. J Biol Chem 285: 7334-7343, 2010.
99. Luk KC, Kehm V, Carroll J, Zhang B, O'Brien P, Trojanowski JQ, and Lee VM. Pathological alpha-synuclein transmission initiates Parkinson-like neurodegeneration in nontransgenic mice. Science 338: 949-953, 2012.
100. Martin LJ, Pan Y, Price AC, Sterling W, Copeland NG, Jenkins NA, Price DL, and Lee MK. Parkinson's disease alpha-synuclein transgenic mice develop neuronal mitochondrial degeneration and cell death. J Neurosci 26: 41-50, 2006.
101. Martin WR, Wieler M, and Gee M. Midbrain iron content in early Parkinson disease: a potential biomarker of disease status. Neurology 70: 1411-1417, 2008.
102. Mena NP, Bulteau AL, Salazar J, Hirsch EC, and Nunez MT. Effect of mitochondrial complex I inhibition on Fe-S cluster protein activity. Biochem Biophys Res Commun 409: 241-246, 2011.
103. Michiorri S, Gelmetti V, Giarda E, Lombardi F, Romano F, Marongiu R, Nerini-Molteni S, Sale P, Vago R, Arena G, Torosantucci L, Cassina L, Russo MA, Dallapiccola B, Valente EM, and Casari G. The Parkinson-associated protein PINK1 interacts with Beclin1 and promotes autophagy. Cell Death Differ 17: 962-974, 2010.
104. Mishra RS, Basu S, Gu Y, Luo X, ZouWQ, Mishra R, Li R, Chen SG, Gambetti P, Fujioka H, and Singh N. Proteaseresistant human prion protein and ferritin are cotransported across Caco-2 epithelial cells: implications for species barrier in prion uptake from the intestine. J Neurosci 24: 11280-11290, 2004.
105. Mishra RS, Bose S, Gu Y, Li R, and Singh N. Aggresome formation by mutant prion proteins: the unfolding role of proteasomes in familial prion disorders. J Alzheimers Dis 5: 15-23, 2003.
106. Molina-Holgado F, Gaeta A, Francis PT, Williams RJ, and Hider RC. Neuroprotective actions of deferiprone in cultured cortical neurones and SHSY-5Y cells. J Neurochem 105: 2466-2476, 2008.
107. Moore DJ, West AB, Dawson VL, and Dawson TM. Molecular pathophysiology of Parkinson's disease. Annu Rev Neurosci 28: 57-87, 2005.
108. Moore RA, Timmes A, Wilmarth PA, and Priola SA. Comparative profiling of highly enriched 22L and Chandler mouse scrapie prion protein preparations. Proteomics 10: 2858-2869, 2010.
109. Mounsey RB and Teismann P. Chelators in the treatment of iron accumulation in Parkinson's disease. Int J Cell Biol 2012: 983245, 2012.
110. Narendra D, Walker JE, and Youle R. Mitochondrial quality control mediated by PINK1 and Parkin: links to parkinsonism. Cold Spring Harb Perspect Biol 4: a011338, 2012.
111. Ng CH, Mok SZ, Koh C, Ouyang X, Fivaz ML, Tan EK, Dawson VL, Dawson TM, Yu F, and Lim KL. Parkin protects against LRRK2 G2019S mutant-induced dopaminergic neurodegeneration in Drosophila. J Neurosci 29: 11257-11262, 2009.
112. Oakley AE, Collingwood JF, Dobson J, Love G, Perrott HR, Edwardson JA, Elstner M, and Morris CM. Individual dopaminergic neurons show raised iron levels in Parkinson disease. Neurology 68: 1820-1825, 2007.
113. Obeso JA, Rodriguez-Oroz MC, Goetz CG, Marin C, Kordower JH, Rodriguez M, Hirsch EC, Farrer M, Schapira AH, and Halliday G. Missing pieces in the Parkinson's disease puzzle. Nat Med 16: 653-661, 2010.
114. Ohgami RS, Campagna DR, McDonald A, and Fleming MD. The Steap proteins are metalloreductases. Blood 108: 1388-1394, 2006.
115. Orru CD, Wilham JM, Hughson AG, Raymond LD, McNally KL, Bossers A, Ligios C, and Caughey B. Human variant Creutzfeldt-Jakob disease and sheep scrapie PrP(res) detection using seeded conversion of recombinant prion protein. Protein Eng Des Sel 22: 515-521, 2009.
116. Palacino JJ, Sagi D, Goldberg MS, Krauss S, Motz C, Wacker M, Klose J, and Shen J. Mitochondrial dysfunction and oxidative damage in parkin-deficient mice. J Biol Chem 279: 18614-18622, 2004.
117. Parihar MS, Parihar A, Fujita M, Hashimoto M, and Ghafourifar P. Mitochondrial association of alpha-synuclein causes oxidative stress. Cell Mol Life Sci 65: 1272-1284, 2008.
118. Parihar MS, Parihar A, Fujita M, Hashimoto M, and Ghafourifar P. Alpha-synuclein overexpression and aggregation exacerbates impairment of mitochondrial functions by augmenting oxidative stress in human neuroblastoma cells. Int J Biochem Cell Biol 41: 2015-2024, 2009.
119. Park J, Lee SB, Lee S, Kim Y, Song S, Kim S, Bae E, Kim J, Shong M, Kim JM, and Chung J. Mitochondrial dysfunction in Drosophila PINK1 mutants is complemented by parkin. Nature 441: 1157-1161, 2006.
120. Parker WD, Jr., Boyson SJ, and Parks JK. Abnormalities of the electron transport chain in idiopathic Parkinson's disease. Ann Neurol 26: 719-723, 1989.
121. Pelizzoni I, Zacchetti D, Smith CP, Grohovaz F, and Codazzi F. Expression of divalent metal transporter 1 in primary hippocampal neurons: reconsidering its role in non-transferrin-bound iron influx. J Neurochem 120: 269-278, 2012.
122. Peng Y, Wang C, Xu HH, Liu YN, and Zhou F. Binding of alpha-synuclein with Fe(III) and with Fe(II) and biological implications of the resultant complexes. J Inorg Biochem 104: 365-370, 2010.
123. Petersen RB, Siedlak SL, Lee HG, Kim YS, Nunomura A, Tagliavini F, Ghetti B, Cras P, Moreira PI, Castellani RJ, Guentchev M, Budka H, Ironside JW, Gambetti P, Smith MA, and Perry G. Redox metals and oxidative abnormalities in human prion diseases. Acta Neuropathol 110: 232-238, 2005.
124. Petrucelli L, O'Farrell C, Lockhart PJ, Baptista M, Kehoe K, Vink L, Choi P, Wolozin B, Farrer M, Hardy J, and Cookson MR. Parkin protects against the toxicity associated with mutant alpha-synuclein: proteasome dysfunction selectively affects catecholaminergic neurons. Neuron 36: 1007-1019, 2002.
125. Polymeropoulos MH, Lavedan C, Leroy E, Ide SE, Dehejia A, Dutra A, Pike B, Root H, Rubenstein J, Boyer R, Stenroos ES, Chandrasekharappa S, Athanassiadou A, Papapetropoulos T, Johnson WG, Lazzarini AM, Duvoisin RC, Di Iorio G, Golbe LI, and Nussbaum RL. Mutation in the alpha-synuclein gene identified in families with Parkinson's disease. Science 276: 2045-2047, 1997.
126. Poulopoulos M, Levy OA, and Alcalay RN. The neuropathology of genetic Parkinson's disease. Mov Disord 27: 831-842, 2012.
127. Prusiner SB. Prions. Proc Natl Acad Sci U S A 95: 13363-13383, 1998.
128. Pushie MJ, Pickering IJ, Martin GR, Tsutsui S, Jirik FR, and George GN. Prion protein expression level alters regional copper, iron and zinc content in the mouse brain. Metallomics 3: 206-214, 2011.
129. Quintana C and Gutierrez L. Could a dysfunction of ferritin be a determinant factor in the aetiology of some neurodegenerative diseases. Biochim Biophys Acta 1800: 770-782, 2010
130. Ramirez A, Heimbach A, Grundemann J, Stiller B, Hampshire D, Cid LP, Goebel I, Mubaidin AF, Wriekat AL, Roeper J, Al-Din A, Hillmer AM, Karsak M, Liss B, Woods CG, Behrens MI, and Kubisch C. Hereditary parkinsonism with dementia is caused by mutations in ATP13A2, encoding a lysosomal type 5 P-type ATPase. Nat Genet 38: 1184-1191, 2006.
131. Riederer P, Sofic E, Rausch WD, Schmidt B, Reynolds GP, Jellinger K, and Youdim MB. Transition metals, ferritin, glutathione, and ascorbic acid in parkinsonian brains. J Neurochem 52: 515-520, 1989.
132. Roth JA, Singleton S, Feng J, Garrick M, and Paradkar PN. Parkin regulates metal transport via proteasomal degradation of the 1B isoforms of divalent metal transporter 1. J Neurochem 113: 454-464, 2010.
133. Rouault TA and Tong WH. Iron-sulphur cluster biogenesis and mitochondrial iron homeostasis. Nat Rev Mol Cell Biol 6: 345-351, 2005.
134. Salazar J, Mena N, Hunot S, Prigent A, Alvarez-Fischer D, Arredondo M, Duyckaerts C, Sazdovitch V, Zhao L, Garrick LM, Nunez MT, Garrick MD, Raisman-Vozari R, and Hirsch EC. Divalent metal transporter 1 (DMT1) contributes to neurodegeneration in animal models of Parkinson's disease. Proc Natl Acad Sci U S A 105: 18578-18583, 2008.
135. Santiago M, Matarredona ER, Granero L, Cano J, and Machado A. Neuroprotective effect of the iron chelator desferrioxamine against MPP + toxicity on striatal dopaminergic terminals. J Neurochem 68: 732-738, 1997.
136. Saunders GC, Horigan V, Tout AC, and Windl O. Identification of a proteinase K resistant protein for use as an internal positive control marker in PrP Western blotting. Res Vet Sci 83: 157-164, 2007.
137. Schapira AH, Cooper JM, Dexter D, Clark JB, Jenner P, and Marsden CD. Mitochondrial complex I deficiency in Parkinson's disease. J Neurochem 54: 823-827, 1990.
138. Scherzer CR, Grass JA, Liao Z, Pepivani I, Zheng B, Eklund AC, Ney PA, Ng J, McGoldrick M, Mollenhauer B, Bresnick EH, and Schlossmacher MG. GATA transcription factors directly regulate the Parkinson's diseaselinked gene alpha-synuclein. Proc Natl Acad Sci U S A 105: 10907-10912, 2008.
139. Shavali S, Brown-Borg HM, Ebadi M, and Porter J. Mitochondrial localization of alpha-synuclein protein in alpha- synuclein overexpressing cells. Neurosci Lett 439: 125-128, 2008.
140. Shendelman S, Jonason A, Martinat C, Leete T, and Abeliovich A. DJ-1 is a redox-dependent molecular chaperone that inhibits alpha-synuclein aggregate formation. PLoS Biol 2: e362, 2004.
141. Shimura H, Hattori N, Kubo S, Mizuno Y, Asakawa S, Minoshima S, Shimizu N, Iwai K, Chiba T, Tanaka K, and Suzuki T. Familial Parkinson disease gene product, parkin, is a ubiquitin-protein ligase. Nat Genet 25: 302-305, 2000.
142. Sian-Hulsmann J, Mandel S, Youdim MB, and Riederer P. The relevance of iron in the pathogenesis of Parkinson's disease. J Neurochem 118: 939-957, 2011.
143. Silvestri L, Caputo V, Bellacchio E, Atorino L, Dallapiccola B, Valente EM, and Casari G. Mitochondrial import and enzymatic activity of PINK1 mutants associated to recessive parkinsonism. Hum Mol Genet 14: 3477-3492, 2005.
144. Singh A, Beveridge AJ, and Singh N. Decreased CSF transferrin in sCJD: a potential pre-mortem diagnostic test for prion disorders. Plos One 6: e16804, 2011.
145. Singh A, Haldar S, Horback K, Tom C, Zhou L, Meyerson H, and Singh N. Prion protein regulates iron transport by functioning as a ferrireductase. J Alzheimers Dis 35: 541-552, 2013.
146. Singh A, Isaac AO, Luo X, Mohan ML, Cohen ML, Chen F, Kong Q, Bartz J, and Singh N. Abnormal brain iron homeostasis in human and animal prion disorders. Plos Pathog 5: e1000336, 2009.
147. Singh A, Kong Q, Luo X, Petersen RB, Meyerson H, and Singh N. Prion protein (PrP) knock-out mice show altered iron metabolism: a functional role for PrP in iron uptake and transport. Plos One 4: e6115, 2009.
148. Singh A, Mohan ML, Isaac AO, Luo X, Petrak J, Vyoral D, and Singh N. Prion protein modulates cellular iron uptake: a novel function with implications for prion disease pathogenesis. Plos One 4: e4468, 2009.
149. Singh A, Qing L, Kong Q, and Singh N. Change in the characteristics of ferritin induces iron imbalance in prion disease affected brains. Neurobiol Dis 45: 930-938, 2012.
150. Singh N, Das D, Singh A, and Mohan ML. Prion protein and metal interaction: physiological and pathological implications. Curr Issues Mol Biol 12: 99-107, 2010.
151. Singh N, Gu Y, Bose S, Basu S, Luo X, Mishra R, and Kuruvilla O. Processing and mis-processing of the prion protein insights into the pathogenesis of familial prion disorders. In: Neurodegeneration and Prion Disease edited by Brown DR New York: Springer, 2005, pp. 299-318
152. Singh N, Gu Y, Bose S, Basu S, Luo X, Ojha A, and Mishra R. The paradoxical role of proteasomes in prion disorders. In The Proteasome in Neurodegeneration edited by Stefanis L and Keller JN New York: Springer, 2006, pp. 265-283.
153. Singh N, Gu YP, Bose S, Kalepu S, Mishra RS, and Verghese S. Prion peptide 106-126 as a model for prion replication and neurotoxicity. Front Biosci 7: A60-A71, 2002.
154. Singh N, Singh A, Das D, and Mohan ML. Redox control of prion and disease pathogenesis. Antioxid Redox Signal 12: 1271-1294, 2010.
155. Singh N, Zanusso G, Chen SG, Fujioka H, Richardson S, Gambetti P, and Petersen RB. Prion protein aggregation reverted by low temperature in transfected cells carrying a prion protein gene mutation. J Biol Chem 272: 28461-28470, 1997.
156. Singleton AB, Farrer M, Johnson J, Singleton A, Hague S, Kachergus J, Hulihan M, Peuralinna T, Dutra A, Nussbaum R, Lincoln S, Crawley A, Hanson M, Maraganore D, Adler C, Cookson MR, Muenter M, Baptista M, Miller D, Blancato J, Hardy J, and Gwinn-Hardy K. Alphasynuclein locus triplication causes Parkinson's disease. Science 302: 841, 2003.
157. Smith WW, Pei Z, Jiang H, Moore DJ, Liang Y, West AB, Dawson VL, Dawson TM, and Ross CA. Leucine-rich repeat kinase 2 (LRRK2) interacts with parkin, and mutant LRRK2 induces neuronal degeneration. Proc Natl Acad Sci U S A 102: 18676-18681, 2005.
158. Sofic E, Paulus W, Jellinger K, Riederer P, and Youdim MB. Selective increase of iron in substantia nigra zona compacta of parkinsonian brains. J Neurochem 56: 978-982, 1991.
159. Solassol J, Crozet C, and Lehmann S. Prion propagation in cultured cells. Br Med Bull 66: 87-97, 2003.
160. Song N, Wang J, Jiang H, and Xie J. Ferroportin 1 but not hephaestin contributes to iron accumulation in a cell model of Parkinson's disease. Free Radic Biol Med 48: 332-341, 2010.
161. Spillantini MG, Schmidt ML, Lee VM, Trojanowski JQ, Jakes R, and Goedert M. Alpha-synuclein in Lewy bodies. Nature 388: 839-840, 1997.
162. Sriram SR, Li X, Ko HS, Chung KK, Wong E, Lim KL, Dawson VL, and Dawson TM. Familial-associated mutations differentially disrupt the solubility, localization, binding and ubiquitination properties of parkin. Hum Mol Genet 14: 2571-2586, 2005.
163. Stichel CC, Zhu XR, Bader V, Linnartz B, Schmidt S, and Lubbert H. Mono- and double-mutant mouse models of Parkinson's disease display severe mitochondrial damage. Hum Mol Genet 16: 2377-2393, 2007.
164. Tanaka Y, Engelender S, Igarashi S, Rao RK, Wanner T, Tanzi RE, Sawa A, Dawson LV, Dawson TM, and Ross CA. Inducible expression of mutant alpha-synuclein decreases proteasome activity and increases sensitivity to mitochondria-dependent apoptosis. Hum Mol Genet 10: 919-926, 2001.
165. Tartakoff AM and Singh N. How to make a glycoinositol phospholipid anchor. Trends Biochem Sci 17: 470-473, 1992.
166. Trancikova A, Tsika E, and Moore DJ. Mitochondrial dysfunction in genetic animal models of Parkinson's disease. Antioxid Redox Signal 16: 896-919, 2012.
167. Uchiyama K, Muramatsu N, Yano M, Usui T, Miyata H, and Sakaguchi S. Prions disturb post-Golgi trafficking of membrane proteins. Nat Commun 4: 1846, 2013.
168. Valente EM, Abou-Sleiman PM, Caputo V, Muqit MM, Harvey K, Gispert S, Ali Z, Del Turco D, Bentivoglio AR, Healy DG, Albanese A, Nussbaum R, Gonzalez- Maldonado R, Deller T, Salvi S, Cortelli P, Gilks WP, Latchman DS, Harvey RJ, Dallapiccola B, Auburger G, and Wood NW. Hereditary early-onset Parkinson's disease caused by mutations in PINK1. Science 304: 1158-1160, 2004.
169. Venderova K, Kabbach G, Abdel-Messih E, Zhang Y, Parks RJ, Imai Y, Gehrke S, Ngsee J, Lavoie MJ, Slack RS, Rao Y, Zhang Z, Lu B, Haque ME, and Park DS. Leucine-rich repeat kinase 2 interacts with parkin, DJ-1 and PINK-1 in a Drosophila melanogaster model of Parkinson's disease. Hum Mol Genet 18: 4390-4404, 2009.
170. Wakabayashi K, Hayashi S, Kakita A, Yamada M, Toyoshima Y, Yoshimoto M, and Takahashi H. Accumulation of alpha-synuclein/NACP is a cytopathological feature common to Lewy body disease and multiple system atrophy. Acta Neuropathol 96: 445-452, 1998.
171. Wang C, Ko HS, Thomas B, Tsang F, Chew KC, Tay SP, Ho MW, Lim TM, Soong TW, Pletnikova O, Troncoso J, Dawson VL, Dawson TM, and Lim KL. Stress-induced alterations in parkin solubility promote parkin aggregation and compromise parkin's protective function. Hum Mol Genet 14: 3885-3897, 2005.
172. Wang F, Wang X, Yuan CG, and Ma J. Generating a prion with bacterially expressed recombinant prion protein. Science 327: 1132-1135, 2010.
173. Wang G, Pan J, and Chen SD. Kinases and kinase signaling pathways: potential therapeutic targets in Parkinson's disease. Prog Neurobiol 98: 207-221, 2012.
174. Winklhofer KF and Haass C. Mitochondrial dysfunction in Parkinson's disease. Biochim Biophys Acta 1802: 29-44, 2010.
175. Winslow AR, Chen CW, Corrochano S, Acevedo-Arozena A, Gordon DE, Peden AA, Lichtenberg M, Menzies FM, Ravikumar B, Imarisio S, Brown S, O'Kane CJ, and Rubinsztein DC. Alpha-synuclein impairs macroautophagy: implications for Parkinson's disease. J Cell Biol 190: 1023-1037, 2010.
176. Wood SJ, Wypych J, Steavenson S, Louis JC, Citron M, and Biere AL. alpha-synuclein fibrillogenesis is nucleation- dependent. Implications for the pathogenesis of Parkinson's disease. J Biol Chem 274: 19509-19512, 1999.
177. Wyman S, Simpson RJ, McKie AT, and Sharp PA. Dcytb (Cybrd1) functions as both a ferric and a cupric reductase in vitro. FEBS Lett 582: 1901-1906, 2008.
178. Xu Q, Kanthasamy AG, and Reddy MB. Neuroprotective effect of the natural iron chelator, phytic acid in a cell culture model of Parkinson's disease. Toxicology 245: 101-108, 2008.
179. Youdim MB, Grunblatt E, and Mandel S. The pivotal role of iron in NF-kappa B activation and nigrostriatal dopaminergic neurodegeneration. Prospects for neuroprotection in Parkinson's disease with iron chelators. Ann N Y Acad Sci 890: 7-25, 1999.
180. Yun SW, Ertmer A, Flechsig E, Gilch S, Riederer P, Gerlach M, Schatzl HM, and Klein MA. The tyrosine kinase inhibitor imatinib mesylate delays prion neuroinvasion by inhibiting prion propagation in the periphery. J Neurovirol 13: 328-337, 2007.
181. Zanusso G, Petersen RB, Jin T, Jing Y, Kanoush R, Ferrari S, Gambetti P, and Singh N. Proteasomal degradation and N-terminal protease resistance of the codon 145 mutant prion protein. J Biol Chem 274: 23396-23404, 1999.
182. Zarranz JJ, Alegre J, Gomez-Esteban JC, Lezcano E, Ros R, Ampuero I, Vidal L, Hoenicka J, Rodriguez O, Atares B, Llorens V, Gomez Tortosa E, del Ser T, Munoz DG, and de Yebenes JG. The new mutation, E46K, of alphasynuclein causes Parkinson and Lewy body dementia. Ann Neurol 55: 164-173, 2004.
183. Zhang Y, Gao J, Chung KK, Huang H, Dawson VL, and Dawson TM Parkin Functions As An E2-dependent Ubiquitin- Protein Ligase and Promotes the Degradation of the Synaptic Vesicle-associated Protein, CDCrel-1. Proc Natl. Acad Sci U S A 97: 13354-13359, 2000.